Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,507 Cr
verified against source
Revenue YoY
-16%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Glenmark's Q3 FY24 consolidated revenue fell 16% YoY to INR 29,096 million, primarily due to a one-time India distribution restructuring that reduced channel inventory. Excluding this, revenue would have grown ~9%. The India business reported primary sales of INR 2,622 million, but secondary sales grew 12%, outperforming the market. North America declined 9% to $91.6 million due to lack of new launches, while Europe grew 29% and ROW 10.8%. Management guided for a significant EBITDA margin improvement in FY25 driven by R&D cost savings of $30-35 million from the IGI alliance, Ryaltris scaling to ~$80 million in sales, and operating leverage. Key risks include execution on the Monroe facility ramp-up and U.S. respiratory launches.
Colored figures show movement against the previous available record.
Guidance to track
- After the one-time restructuring, India primary sales will normalize to ~INR 1,000 crore per quarter, growing 10-12% YoY.
- Management expects Ryaltris to generate ~$80 million in booked sales in FY25, with high margins.
- IGI alliance will lower annual R&D spend from $75-80 million to $45-50 million, boosting EBITDA.
- Proceeds from GLS divestment (~INR 5,000 crore net) will make the company net cash positive by March 2024.
Risks flagged
- Monroe plant is awaiting FDA inspection; any delay in approval or commercialization could impact injectable revenue and margin improvement.
- Generic Flovent pMDI NDA filing expected in Q1 FY25, but approval and launch timing remain uncertain, affecting U.S. growth trajectory.
- Despite guidance of INR 1,000 crore quarterly run rate, the one-time restructuring impact may have lingering effects on channel dynamics.
Key quotes
- We've done a lot of restructuring, right? This is all part of the overall restructuring that we are doing in terms of our innovation across the company, right? And with this heightened focus and synergies that will come out of this alliance, right, we believe there will be a significant improvement in terms of our bond, right, on innovation.
- Next year's EBITDA number, right, you'll see a significant bump-up. This is one of the key drivers. But in addition, also, because of Ryaltris and some of the other operating leverage that we are seeing in geographies like Latin America, Europe, which has always been a low-margin business for us now with the scale that we are gaining in Europe and Latin America, right, all that should help drive EBITDA strong next year.
- We think this will be the next Ryaltris for the company. So the next 3 years-4 years, we think Ryaltris will dominate, and thereafter, envafolimab can be the next Ryaltris for us, right, especially operating in a very large market.
Research modules